With data from the first clinical trial of anti-TNF polyclonal antibody AVX-470 in ulcerative colitis (UC) due toward the end of this year, Avaxia Biologics Inc. shored up its balance sheet with an additional $5 million, bringing its total Series B funding to $11.4 million.